Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Amyloid and Glucose PET Imaging in Alzheimer and Vascular Cognitive Impairment Patients With Significant White Matter Disease

NCT02330510 is registered in ClinicalTrials.gov with Dr. Sandra E Black as lead sponsor.

NCT NCT02330510
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02330510 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Amyloid and Glucose PET Imaging in Alzheimer and Vascular Cognitive Impairment Patients With Significant White Matter Disease
Lead sponsor
Dr. Sandra E Black
Phase
Observational
Overall status
Completed
Start date
August 31, 2014
Completion date
December 10, 2024
Enrollment
80 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer's disease, small vessel disease white matter hyperintensities subtype, vascular cognitive impairment